New Key Statistics Module, Z-Score and F-Score
NAS:XFOR Key Ratios
| Market Cap $ M | 66.41 |
| Enterprise Value $ M | 9.64 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 1.10 |
| Price/Sales | 64.90 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 1.00 |
| EPS (TTM) $ | -0.08 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 54.70 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -1.16 |
| EV-to-EBITDA | -1.25 |
| PEG | -- |
| Shares Outstanding M | 170.55 |
| Net Margin (%) | -1,492.34 |
| Operating Margin % | -11,654.94 |
| Pre-tax Margin (%) | -1,484.77 |
| Quick Ratio | 4.80 |
| Current Ratio | 4.89 |
| ROA % (ttm) | -10.20 |
| ROE % (ttm) | -30.60 |
| ROIC % (ttm) | -346.83 |
| Dividend Yield % | -- |
| Altman Z-Score | -2.78 |
XFOR Number of Guru Trades
XFOR Volume of Guru Trades
Gurus Latest Trades with NAS:XFOR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:XFOR is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
X4 Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:XFOR
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers